Efficacy and safety of three species of Rhodiola L. in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

Chronic obstructive pulmonary disease (COPD) is characterized by chronic hypoxia, inflammation, oxidative stress, and irreversible airflow limitations. L is a genus of botanical drugs used in traditional medicine that may influence COPD. A systematic review of the safety and efficacy of L. in patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in pharmacology 2023-04, Vol.14, p.1139239-1139239
Hauptverfasser: Yu, Haichuan, Lei, Ting, Su, Xiaojie, Zhang, Lu, Feng, Zhouzhou, Dong, Mengya, Hou, Zheyu, Guo, Hong, Liu, Jian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chronic obstructive pulmonary disease (COPD) is characterized by chronic hypoxia, inflammation, oxidative stress, and irreversible airflow limitations. L is a genus of botanical drugs used in traditional medicine that may influence COPD. A systematic review of the safety and efficacy of L. in patients with COPD. We searched the PubMed, Embase, Cochrane Library, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, and SinoMed databases. The search strategy used terms including "COPD" and "Rhodiola." Two independent reviewers conducted the literature screening, data extraction, and risk of bias assessment, with a third reviewer involved to resolve disagreements. Statistical analysis was conducted in Review Manager (version 5.4.1), following the Cochrane Handbook. This review included nine studies, of which two focused on (Hook.f. and Thomson) H. Ohba (R. ) and two on (Regel) Maxim (R. ); the remaining five focused on (Hook.) S.H.Fu (R. ). Compared with the placebo, patients who received L. presented no more adverse events ( = 0.65) but showed significant improvement in the percentage of forced expiratory volume in 1 s at prediction (FEV1%pred), forced expiratory volume in 1 s (FEV1), the ratio of forced expiratory volume in 1 s on forced vital capacity (FEV1/FVC), saturation of oxygen in arterial blood, partial pressure of oxygen in arterial blood (PaO ), partial pressure of carbon dioxide in arterial blood (PaCO ), systolic pulmonary arterial pressure, diastolic pulmonary arterial pressure, COPD assessment test, efficient rate, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (all < 0.01). Compared with ambroxol, R. provided additional benefits to patients with COPD in FEV1%pred, FEV1, FEV1/FVC, PaO2, PaCO2, 8-iso-prostaglandin F2α, superoxide dismutase, glutathione, malondialdehyde, and total antioxidant capacity (all < 0.01). Among the L. genus, this review included R. , R. , and R. , which might be safe and effective in COPD. Although this study has several limitations, further RCTs are needed. : [https://www.crd.york.ac.uk/PROSPERO/ display_record.php?RecordID=302881], identifier [CRD42022361890].
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1139239